Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sac-TMT Combined With KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer
NCT07258108Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2025
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan, tagitanlimab in breast cancer, sponsored by Sun Yat-sen University. Started Nov 2025; status: recruiting.
02
Drugs
sacituzumab tirumotecantagitanlimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07258108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07258108.